Gastrointestinal bleeding from angiodysplasia is a major problem in continuous-flow left ventricular assist device (LVAD) patients. LVAD shear stress causes pathologic degradation of VWF (von Willebrand factor). A mechanistic relationship between VWF degradation and angiodysplasia has not been explored. We tested 2 novel hypotheses: (1) clinical hypothesis: VWF fragments are elevated in LVAD patients that develop angiodysplasia and (2) in vitro hypothesis: VWF fragments generated during LVAD support alter angiogenesis, which may contribute to angiodysplasia.
G
astrointestinal bleeding is a major source of morbidity and costs in patients with a continuous-flow left ventricular assist device (LVAD). 1, 2 Angiodysplasia is the most frequent source of bleeding. [3] [4] [5] [6] It is unknown why LVAD patients develop angiodysplasia and bleed. Mechanistic relationships between LVAD support, abnormal angiogenesis, angiodysplasia, and bleeding are poorly understood.
Recent evidence suggests that LVAD support alters systemic angiogenic signaling 7, 8 and causes abnormal angiogenesis 8 in mucosal tissues. As a result, LVAD support leads to nasopharyngeal hypervascularization 9 and what is likely a distinct form of gastrointestinal angiodysplasia. 10 The pathophysiologic mechanism(s) of these changes have not been described.
It is well established that supraphysiologic shear stress within continuous-flow LVADs accelerates the degradation of VWF (von Willebrand factor). 11 During this process, VWF multimers are degraded into VWF fragments, which accumulate in the blood. Systemic effects of VWF fragments circulating chronically are unknown. However, VWF is a key regulator of normal angiogenesis. 12 As such, it is conceivable that VWF degradation contributes to angiodysplasia through abnormal angiogenic signaling.
Interestingly, there is significant clinical evidence that abnormal VWF metabolism is present in multiple patient populations that develop angiodysplasia. For example, in patients with Heyde's syndrome, critical aortic stenosis causes shear stress-induced VWF degradation and gastrointestinal bleeding from angiodysplasia. 13 Similarly, patients with congenital and acquired von Willebrand's syndrome exhibit an increased incidence of gastrointestinal angiodysplasia. 14, 15 These similarities suggest that mechanistic relationships exist between abnormal VWF and angiodysplasia.
With this in mind, we investigated relationships between VWF degradation during LVAD support, abnormal angiogenesis, and angiodysplasia. We tested 2 novel hypotheses: (1) clinical hypothesis: VWF degradation fragments are elevated in LVAD patients that develop gastrointestinal angiodysplasia and (2) in vitro hypothesis: VWF fragments generated during LVAD support alter angiogenesis, which may contribute to angiodysplasia. Endothelial cell tubule formation and endothelial cell migration, activities that are critical to normal angiogenesis, were evaluated with standard cell culture assays.
MATERIALS AND METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Clinical Study
Blood samples were obtained from LVAD patients and volunteer donors with approval from the Hospital of the University of Pennsylvania Institutional Review Board (number 818944). Subjects provided informed consent. Patient samples were collected between December 2013 and December 2016. Patients demographics were collected from the patient medical record (Table 1) .
All patients were maintained on Coumadin (INR, 2.2-2.8) and administered aspirin 325 mg unless a contraindication existed.
Fresh, whole blood was obtained from patients before implantation of a clinically approved continuous-flow LVAD and after 1 week of LVAD support (n=35). VWF degradation is an early-onset phenomenon that is present within 24 hours of the initiation of LVAD support. 16 Therefore, for each patient, a 1-week sample with LVAD-induced VWF degradation was compared directly to a paired pre-LVAD sample from the same patient.
After an average of 666±430 days of support, patients were characterized as nonbleeders, gastrointestinal bleeders without angiodysplasia, or gastrointestinal bleeders with endoscopically confirmed angiodysplasia. Angiodysplasia was diagnosed via upper, lower, or pill endoscopy. Gastrointestinal bleeders without angiodysplasia underwent endoscopy that
WHAT IS NEW?
• In a clinical study, we observed that patients with a continuous-flow left ventricular assist device (LVAD) with gastrointestinal angiodysplasia had higher levels of VWF (von Willebrand factor) fragments than nonbleeders or gastrointestinal bleeders without angiodysplasia.
• Our in vitro experiments demonstrated that plasma from LVAD patients (with degraded VWF and high levels of VWF fragments) caused abnormal angiogenesis. Toward understanding mechanism, in separate experiments, purified VWF degradation fragments caused the same profile of abnormal angiogenesis.
• These findings support the novel hypothesis that LVAD-induced VWF degradation alters angiogenesis and may play a role in LVAD-associated angiodysplasia.
WHAT ARE THE CLINICAL IMPLICATIONS?
• During prolonged LVAD support, VWF degradation may alter systemic angiogenic signaling and contribute to abnormal mucosal vascularization and bleeding.
• With this in mind, targeted therapies designed to preserve VWF multimers and to correct angiogenic imbalance may reduce the incidence of LVAD-associated bleeding.
• Alternatively, future-generation LVADs designed to minimize shear stress and LVAD-induced blood trauma may reduce pathologic VWF degradation, angiodysplasia, and bleeding.
was negative for angiodysplasia as the source of bleeding. VWF multimers and fragments were quantified with electrophoresis and immunoblotting ( Figures 1A, 2B , and 3B) as described below.
In Vitro Experiments
Two hypotheses were tested in 2 in vitro experiments: (1) LVAD patient plasma causes abnormal angiogenesis-endothelial cells were cultured with LVAD patient plasma and (2) VWF fragments generated during LVAD support alter angiogenesis-endothelial cells were cultured with VWF fragments.
Angiogenic Potential of LVAD Patient Blood
To determine whether plasma from LVAD patients alters angiogenesis in vitro, paired samples of fresh, whole blood were obtained from LVAD patients (n=11) before and during support with a clinically approved continuous-flow LVAD. As a control, fresh whole blood was obtained from healthy human donors (n=8). VWF degradation was characterized with electrophoresis and immunoblotting ( Figure 2B ). Endothelial cells were cultured with 20% LVAD patient plasma plus 80% endothelial basal media (EBM, Lonza, Basel, Switzerland).
Ex Vivo Model of LVAD Blood Trauma
To produce the same profile of VWF fragments generated during continuous-flow LVAD support, we previously developed a clinically relevant ex vivo LVAD blood-trauma model. 17 In this tightly controlled model, plasma samples were exposed to a continuous cyclone spin in a laboratory vortexer (Vortex Genie-2, Scientific Industries, Bohemia, NY). At 2400 rpm, the vortexer generates supraphysiologic shear stress of ≈175 dyne/cm 2 , which is an order of magnitude greater than physiologic values. For comparison, current generation continuous-flow LVADs generate shear stress 1 to 2 orders of magnitude greater than physiologic values.
18,19

Production of VWF Degradation Fragments
To determine the effect of VWF fragments on angiogenesis (independent of other plasma proteins), we generated LVAD VWF fragments as previously described. 11 Purified, intact (full-length) human VWF multimers (Thermofisher Scientific, Waltham, MA) and recombinant, full-length human ADAMTS-13 (a disintegrin and metalloproteinase thrombospondin-like motif-13) protein (R&D Systems, Minneapolis, MN) were obtained. VWF multimers (10 μg/mL) plus ADAMTS-13 protein (0.5 μg/mL) were prepared in EBM at physiologic concentrations. 11, 20 Samples were exposed to LVAD-like shear stress (≈175 dyne/cm 2 ) for 4 hours. This technique generated a similar profile of VWF fragments to an LVAD patient. Fragments were used for endothelial cell culture experiments. VWF degradation was characterized with electrophoresis and immunoblotting ( Figure 3B ). Endothelial cells were cultured with either intact VWF multimers (full-length, not exposed to shear stress) as a control or with VWF fragments (generated with shear stress) in EBM. In a negative control, endothelial cells were cultured with EBM alone.
Endothelial Cell Culture and Quantification of Angiogenesis
Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured in buffered endothelial growth media (Lonza) at 37°C with 5% CO 2 . Third or fourth passage cells were used. Before experiments, HUVECs were trypsinized and washed with EBM. Cells were viewed with light or epifluorescence microscopy and analyzed with ImageJ (National Institutes of Health, Bethesda, MD).
Total endothelial tubule length per unit area, an established angiogenesis assay that evaluates the ability of the endothelium to sprout and form early vascular tubules, was quantified. HUVECs were cultured on Matrigel (Corning Lifesciences, Tewksbury, MA) at a density of ≈30 000 cells/cm 2 and incubated during each treatment condition. Cells were imaged at baseline and after 8 hours of growth.
Endothelial cell migration, another established angiogenesis assay that evaluates the ability of the endothelium to mobilize when stimulated, was quantified with a scratch/ wound healing assay. HUVECs were plated in endothelial growth media with a density of ≈2000 cells/cm 2 at ≈90% confluence. Cells were washed in EBM, and media was replaced with experimental samples. Uniform wounds of ≈1 mm were administered with a 200 μL micropipette. Images were obtained at baseline (immediately after wounding) and after 18 hours of migration. Migration was quantified by subtracting the average wound width at 3 random sites from the average width at baseline.
As a control, cellular survival was quantified with the LIVE/ DEAD Cytotoxicity Kit (Thermofisher Scientific) as viable cells divided by total cells per unit area for each experiment.
Gel Electrophoresis and Immunoblotting for VWF Multimers and Fragments
High-molecular-weight plasma VWF multimers were analyzed by standard electrophoresis and immunoblotting techniques. 11, 17, 20, 21 Plasma was diluted in LDS loading buffer, heated, and loaded into vertical 1% agarose-SDS gels. Electrophoresis was performed in Tris-Acetate SDS running buffer (Invitrogen, Carlsbad, CA) in an XCell SureLock MiniCell Electrophoresis System (Invitrogen).
Proteins were transferred to PVDF using the iBlot dry transfer device (Invitrogen). Membranes were blocked and incubated with rabbit anti-human VWF primary antibody (1:500, Dako, Carpinteria, CA) overnight. Membranes were incubated with goat anti-rabbit IgG horseradish peroxidaseconjugated secondary antibody (1:3,000, Cell Signaling, Danvers, MA), developed with Luminata Forte Western blot Pre-LVAD, n=11
Fragments LVAD, n=11
Pre-LVAD, n=11 horseradish peroxidase substrate (Millipore, Billerica, MA), and imaged with an ImageQuant LAS 4000 (GE Healthcare, Piscataway, NJ). VWF fragments were analyzed by standard electrophoresis and immunoblotting techniques. 11, 17, 20, 21 Plasma was diluted in NuPAGE LDS sample buffer (Invitrogen), heated, and loaded into NuPAGE 3% to 8% Tris-Acetate Polyacrylamide gels (Invitrogen). Electrophoresis was performed in TrisAcetate SDS running buffer (Invitrogen). Protein was transferred, blocked, probed for VWF, and imaged as described above. As a loading control, each membrane was probed for human plasma albumin with a goat anti-human albumin horseradish peroxidase-conjugated antibody (1:5000 Abcam, Cambridge, MA).
Quantification of VWF
Paired plasma samples from each patient were blotted in adjacent lanes. The loss of high-molecular-weight VWF multimers was quantified as the percent decrease in total length of multimers during LVAD support versus baseline. Low-molecular-weight VWF was quantified as percent change in area under the curve for the lowest-molecular-weight band. VWF fragments were quantified as the mean change in amplitude of all degradation fragments. ImageQuantTL (GE Healthcare) and ImageJ were used to generate and analyze densitometric plots, respectively.
Statistics
GraphPad, version 6.00 (Prism, GraphPad Software, Inc, La Jolla, CA) was used to perform statistical analyses and plot data. To assess for normality, Kolmogorov-Smirnov tests were performed for all data variables. All data were normal with the exception of age and days of support to first bleed. Parametric data were analyzed as appropriate with ordinary 1-way ANOVA with Tukey post-test, paired, or unpaired Student t tests. Nonparametric data were analyzed as appropriate with Kruskal-Wallis with Dunn post-test or Mann-Whitney U test. Categorical data were analyzed with χ 2 tests. A P<0.05 was considered statistically significant. Descriptive data in the text and tables were presented as mean±SD. Data in figures were presented as mean±SE.
RESULTS
Patient Outcomes
Thirty-five patients underwent continuous-flow LVAD support for an average of 666±430 days. Seven patients developed gastrointestinal bleeding from endoscopically confirmed gastrointestinal angiodysplasia (mean 105±127 days, median 34 days of support at first bleed, interquartile range 214 days). Six patients developed gastrointestinal bleeding without angiodysplasia (mean 137±113 days, median 121 days of support at first bleed, interquartile range 178 days).
Aspirin was administered to 95% of nonbleeders (21 out of 22 patients) for the duration of the study. In the remaining patient, aspirin was discontinued after an intracranial bleed. At the time of gastrointestinal bleeding, 100% of patients (7/7) that bled from angiodysplasia were receiving aspirin whereas 83% of patients (5/6) that bled without angiodysplasia as the confirmed source were receiving aspirin. In the remaining patient, aspirin was discontinued after an intracranial bleed before their index gastrointestinal bleed.
Profile of LVAD-Associated VWF Degradation
Each LVAD patient (n=35) exhibited a consistent profile of VWF degradation versus their paired pre-LVAD sample ( Figure 2B ). As previously reported in this cohort of patients, high-molecular-weight VWF multimers decreased significantly (P<0.0001) and low-molecularweight VWF multimers (P<0.0001) and VWF fragments increased significantly (P<0.0001) compared with pre-LVAD values. 10 In 7 patients that bled from endoscopically confirmed gastrointestinal angiodysplasia, VWF fragments were significantly elevated versus nonbleeders (Figure 1 ; Table 2 ; 184±44% versus 149±31%; P=0.02). In contrast, in 6 patients that bled without gastrointestinal angiodysplasia, VWF fragments were not significantly elevated versus nonbleeders (149±54% versus 149±31%; P=0.96). Levels of high-molecular-weight (P=0.24 and P=0.24) and low-molecular-weight (P=0.90 and P=0.86) VWF multimers were not significantly different between nonbleeders and bleeders with or without angiodysplasia.
Angiogenesis With Plasma From LVAD Patients
Paired pre-LVAD and LVAD plasma (with increased VWF fragments) from patients (n=11) altered angiogenesis in vitro (Figure 2 ; Table 3 ). Compared with pre-LVAD samples, LVAD plasma significantly reduced total endothelial tubule length (32±14 versus 22±11 mm/ cm 2 , P=0.04) and migration (675±85 versus 570±101 µm, P=0.05). Significant differences were not observed between normal controls and pre-LVAD samples (Table 3) . Endothelial cell survival was not different across groups (control, 99±2; pre-LVAD, 99±2; LVAD, 99±1; P=0.92).
Angiogenesis With VWF Degradation Fragments
Exposure of intact (full-length) VWF multimers plus ADAMTS-13 protein to LVAD-like shear stress produced a similar pattern of VWF degradation to LVAD patients ( Figure 3B ). VWF multimers were absent. VWF fragments accumulated in large quantity.
Endothelial cells (≈30 000 cells/cm 2 , n=8/group) grown with intact VWF multimers exhibited significantly increased migration (P=0.009) and no change in tubule formation (P=0.52) compared with the EBM negative control (without VWF).
In contrast, angiogenesis was abnormal when endothelial cells (≈30 000 cells/cm 2 , n=8/group) were grown in vitro with VWF fragments compared with intact VWF multimers ( Figure 3 ; Table 3 
DISCUSSION
These data demonstrate relationships between continuous-flow LVAD support, VWF degradation, abnormal angiogenesis, gastrointestinal angiodysplasia, and bleeding. Our findings support the novel hypothesis that pathologic VWF metabolism contributes to gastrointestinal angiodysplasia and bleeding in continuous-flow LVAD patients. Specifically, in a clinical study, (1) LVAD support degraded VWF multimers into VWF fragments and (2) patients who bled from gastrointestinal angiodysplasia exhibited higher levels of VWF fragments than nonbleeders, whereas patients without angiodysplasia that developed gastrointestinal bleeding did not. Separately, in vitro experiments demonstrated that (1) plasma from LVAD patients reduced endothelial cell tubule formation and migration and (2) VWF fragments reduced endothelial cell tubule formation and migration. These findings support a 2-hit hypothesis for LVADassociated gastrointestinal bleeding (Figure 4) . Pathologic VWF degradation from a continuous-flow LVAD causes an acquired VWF deficiency, reduces VWF-collagen and VWF-platelet binding, and results in a bleeding diathesis (hit 1). In parallel, VWF fragments alter angiogenesis, which contributes to angiodysplasia and bleeding (hit 2).
LVAD-Associated Gastrointestinal Bleeding From Angiodysplasia Is a Major Problem
Nonsurgical bleeding is a major source of morbidity and an obstacle to improving outcomes, reducing costs, and expanding the public health impact of mechanical circulatory support. 1, 2, 22 Approximately 18% to 40% of patients develop gastrointestinal bleeding. 5, 6, 23 The most common source is angiodysplasia.
3-6,24
Continuous-Flow LVADs Cause Pathologic VWF Degradation
There is mounting evidence that accelerated VWF metabolism plays an important role in LVAD-associated bleeding. VWF, a large multimeric glycoprotein, circulates in the plasma and plays a critical, initial role in primary hemostasis. VWF metabolism is closely regulated by the rheologic conditions of the blood. 25 Shear stress causes the VWF-specific protease, ADAMTS-13, 25, 26 to degrade VWF multimers into VWF fragments. In normal humans, shear stress is low, and this process occurs at a low level. Many VWF multimers and few VWF fragments circulate in the blood, and the ratio of VWF multimers to fragments is high.
In contrast, current generation continuous-flow LVADs generate shear stress 1 to 2 orders of magnitude greater than physiologic values. 18, 19 As a result, 2 biophysical mechanisms cause pathologic VWF degradation 11 : (1) major mechanism-enzymatic degradationshear stress changes the tertiary structure of globular (inactive) VWF into elongated (active) VWF. This exposes ADAMTS-13 cleavage sites and enzymatic degradation of VWF occurs ( Figure 4 ) and (2) minor mechanism-nonenzymatic degradation-shear stress, itself tears apart disulfide bridges within VWF multimers independent of ADAMTS-13 cleavage. This lesser pathway produces 225 kDa VWF monomers 21 (individual VWF subunits) that are not normally generated by ADAMTS-13 cleavage. In LVAD patients, these parallel pathways rapidly degrade VWF multimers into VWF fragments, some of which are not normally present in the circulation. In these patients, the ratio of VWF multimers to fragments is low. Reduced VWF multimers decreases platelet and collagen binding to VWF. Primary hemostasis becomes impaired, which predisposes patients to bleeding (Figure 4) . Systemic effects of absent VWF multimers and elevated VWF fragments circulating chronically in the body are largely unknown. Heyde's syndrome 13 (the constellation of aortic stenosis, an acquired VWF deficiency, and gastrointestinal bleeding from angiodysplasia) provides clues about angiogenic effects of pathologic VWF metabolism. In these patients, high shear stress through the stenotic aortic valve accelerates VWF degradation. 27 VWF multimers are degraded into VWF fragments, and the ratio of VWF multimers to fragments is again low. Approximately 10% of patients present with gastrointestinal bleeding from angiodysplasia 28 at a rate of 100-fold greater than the general population. 29 These findings highlight clinical relationships between abnormal shear stress, pathologic VWF metabolism, gastrointestinal angiodysplasia, and bleeding.
Patients with congenital von Willebrand's disease also develop angiodysplasia. Approximately 37% of patients with type 2A (congenital) von Willebrand's disease present with gastrointestinal bleeding, 30 frequently from angiodysplasia. 14, 15, 30 Similarly, the prevalence of angiodysplasia in type 2B von Willebrand's disease is 12%.
14 These clinical observations again suggest a causal relationship between VWF and angiodysplasia. The mechanistic basis for this relationship is unknown. However, we again point out that in these patients with low levels of VWF multimers, the ratio of circulating VWF multimers to fragments is low. It is possible that the ratio of VWF multimers to fragments in patients with congenital von Willebrand's disease (as well as in patients with an LVAD or Heyde's syndrome) is important for systemic angiogenic signaling and may be a common trigger for angiodysplasia.
LVAD-Associated Gastrointestinal Angiodysplasia May Be a Distinct Pathology
Angiodysplasia is a poorly understood manifestation of dysregulated angiogenesis. Molecular mechanisms are poorly characterized. A loss of balance between neovascular proliferation and stabilization during angiogenesis causes dysfunctional, friable vessels. Clinically, angiodysplasia presents in the gastrointestinal submucosa as thin-walled, ectatic vascular structures with little smooth muscle. The most common form, age-related angiodysplasia, typically develops in the large bowel, 31, 32 where luminal wall tension is highest. 30, 31 Over time, venous outflow obstruction causes dilation of venules and arteriovenous connections form. Angiogenic imbalance with aberrant VEGF (vascular endothelial growth factor) signaling has also been implicated. 33, 34 In contrast, in LVAD patients, most angiodysplasia occurs in the small bowel and upper gastrointestinal tract 24 (not the large bowel). In these areas, wall tension is low and does not cause venous dilation or arteriovenous connections. This suggests that different triggers for angiodysplasia exist in LVAD patients and that LVADassociated angiodysplasia may be a distinct pathology. 10 Indeed, there is growing evidence that continuousflow LVAD support alters systemic vascular structure and function, angiogenic signaling, and angiogenesis. Nonphysiologic hemodynamics generated by LVADs activate endothelial cells, 35 trigger arterial remodeling, 36, 37 and alter arterial function. 37 Patients develop elevated plasma levels of cyclic guanosine monophosphate 7 and angiopoietin-2 8 . Interestingly, cyclic guanosine monophosphate and angiopoietin-2 are downstream effectors of VWF. 33, 38 We speculate that LVAD-induced VWF degradation is an early upstream signal that causes increased cyclic guanosine monophosphate and angiopoietin-2 levels, which cause abnormal angiogenesis. 8 As a result, nasal mucosal vascular proliferation 9 and intestinal angiodysplasia 10 occur.
Abnormal VWF Metabolism May Link LVAD Support, Abnormal Angiogenesis, and Angiodysplasia
VWF plays a regulatory role in at least 20 molecular pathways involved in vascular inflammation, endothelial cell life cycle, smooth muscle proliferation, arterial remodeling, and angiogenesis. 12, 33, 39 There is strong evidence that VWF represses angiogenesis in vivo. 12 Endothelial cells from patients with von Willebrand's disease exhibit increased VEGF-dependent capillary network formation. 12 Similarly, VWF knockout mice exhibit systemic hypervascularization. 12 These experiments demonstrate that normal VWF multimers are necessary for normal angiogenesis. Extrapolating to our data, abnormal VWF degradation may alter systemic angiogenic signaling. LVAD support degrades a single 20 000 kDa high-molecular-weight VWF multimer into nearly one hundred 225-, 140-, and 176-kDa VWF fragments. As a result, the total number of individual VWF peptides (VWF fragments, which have biological activity 40 ) circulating in the blood increases significantly. The burden of increased fragments may alter constitutive angiogenesis throughout the body. This effect may be the most prominent in mucosal tissues which have a high turnover rate and constant angiogenesis. For example, mucosa of the nasopharynx and gastrointestinal tract (established sites of LVAD-associated angiodysplasia) 9,10 continuously proliferates, remodels, and sloughs. In these tissues, vascular structures con-stantly form, remodel, and involute. We speculate that tissues with a high turnover rate are more susceptible to abnormal angiogenic signals versus tissues in which vascular structures are relatively static.
Clinical Translation
Gastrointestinal bleeding in LVAD patients is poorly understood. Clinical management remains a challenge because targeted therapies do not exist. Blood transfusion, reduced anticoagulation, cessation of antiplatelet therapy, and endoscopic intervention treat the bleeding event but do not address the underlying pathology. Similarly, pharmacotherapy with octreotide, 41 arginine vasopressin, 42 danazol, 43 synthetic estrogens, 44 and Wilfactin 45 have anecdotal success but have not been widely adopted. These therapies likely do not target specific triggers of LVAD-associated angiodysplasia.
During prolonged LVAD support, degraded VWF may alter the systemic balance of angiogenic signals. Abnormal angiogenesis in bowel mucosa may promote angiodysplasia and bleeding ( Figure 4 ). If this proves to be correct, targeted therapies designed to preserve VWF multimers 20 and correct angiogenic imbalance 46 may have clinical utility. For example, thalidomide, a potent antiangiogenic agent, prevented recurrent gastrointestinal bleeding in a randomized clinical trial 47 and a series of LVAD patients. 46 These findings further support the concept that abnormal angiogenesis causes (and may be targeted to treat) LVAD-associated angiodysplasia. 8 Alternatively, future-generation LVADs designed to minimize shear stress may reduce pathologic VWF degradation, 48 angiodysplasia, and bleeding.
Limitations
This study does not establish causality between VWF fragments and angiodysplasia. Our clinical findings that bleeders with angiodysplasia had significantly elevated VWF fragments provided only indirect evidence of a causal relationship between VWF degradation and angiodysplasia. Similarly, our in vitro studies did not examine the direct relationship between abnormal angiogenesis and angiodysplasia. Additional clinical and in vitro studies are needed to further clarify these complex relationships. A potential limitation was the small number of patients studied and samples used in the in vitro experiments. There is a risk that observed effects could be driven by chance findings from a few samples (type I statistical error). Encouragingly, patients demonstrated consistent and robust biological changes. Moreover, 2 separate in vitro experiments demonstrated similar findings across 2 separate functional angiogenesis assays. Nevertheless, with a small sample size, we may have failed to detect important effects (type II statistical error). The lack of borderline statistically significant P values (P≈0.10) suggested that this was not the case.
Characteristics of our patient population presented a methodologic dilemma. In 6 of 13 patients with gastrointestinal bleeding, angiodysplasia was not identified as the source. Rather than excluding these patients because they did not fit into the nonbleeder group or the angiodysplasia bleeder group, we included them as a separate group. It is possible that they represent a separate bleeding pathophysiology. We speculate that there may be 2 groups of LVAD gastrointestinal bleeders: 1 group in which VWF fragments contribute to a distinct form of angiodysplasia 10 and bleeding and 1 group that is independant of angiodysplasia but exacerbated by LVAD-associated acquired VWF deficiency.
Bleeding during LVAD support is multifactorial. This study only investigated the role of pathologic VWF degradation in angiodysplasia-related bleeding. The roles of anticoagulation and antiplatelet therapy, patient hematologic variability, LVAD blood trauma, systemic inflammation from chronic disease, and other contributors to LVAD-associated bleeding need further investigation.
Conclusions
LVAD patients who bled from angiodysplasia had higher levels of VWF fragments than nonbleeders. In vitro, plasma from LVAD patients (with high levels of VWF fragments) and purified VWF fragments caused abnormal angiogenesis.
VWF degradation may be an important mechanistic link between LVAD support, abnormal angiogenesis, and gastrointestinal angiodysplasia and bleeding by 2 parallel mechanisms (2-hit hypothesis). Abnormal VWF metabolism leads to an acquired VWF deficiency and a predisposition to bleeding (hit 1). In parallel, VWF degradation alters mucosal angiogenesis, which contributes to angiodysplasia and bleeding (hit 2). A similar pathologic mechanism may occur in other pathologies associated with abnormal VWF, such as Heyde's syndrome and congenital von Willebrand's disease. 
